ABSTRACT
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, idiopathic lung disease of unknown etiology. The pathogenesis of IPF is characterized by fibroproliferative response uniformly accompanied by type II cell hyperplasia (1) . For optimal therapeutic management of IPF an accurate tool is required for discrimination between reversible and irreversible types of the disease. However, such noninvasive tools are few, and even with high-resolution computed tomography (HRCT), which is the most trusted method for doing so; the nature of the disease activity in IPF cannot always be accurately predicted. Current therapies are only marginally effective in improving pulmonary function or survival time.
The hydrophilic surfactant proteins (SP)-A and SP-D belong to the collection subgroup of the C-type lectin superfamily, along with mannose-binding glycoproteins and collectin CL43 (2) . Two types of nonciliated epithelial cells, in the peripheral airways, Clara cells and alveolar type II cells produce these lung collectins (3) . Surfactant proteins -D (SP-D), produced and secreted by type II cells, can be detected in serum and are elevated in patients with certain inflammatory lung diseases (3, 4, 5) . Although the exact mechanism for the increase in SP-D in the circulation is not known, it is probably a combination of loss of epithelial integrity due to injury and an increased mass of type II cells due to hyperplasia.
Because the concentrations of serum SP-D probably vary with disease and lung inflammation, measurement of this protein might prove to be useful markers for detecting the pathogenesis and follow up of patients with IPF (6,7,8) .
The aim of the present study is to investigate the possible role of SP-D in the pathogenesis and prognosis of idiopathic pulmonary fibrosis patients and its value in making clinical choices for therapeutic management of these patients. Ten ml. peripheral venous blood samples were collected from the patients at their initial visits and from healthy subjects at the time of registration for the study. The serum samples had been stored at 80°C and were analyzed in a blindedfashion with regard to the clinical status of the patients.
SUBJECTS & METHODS

Statistical Analysis
Data are expressed as mean ± SD. Differences between SP-D values on the three study groups, variables were assessed with the Mann-Whitney U test. The concentrations of SP-D were further analyzed by using student "t" test for the healthy group in order to find the cutoff levels indicating the best sensitivity and specificity of these two measures (12) . Significance was defined as p < 0.05.
RESULTS
The results of the study are summarized in tables 1-4 and figures 1-4. Table ( 2) showed significant decrease in FEV1/FVC % in the three diseased groups compared to control. No significant difference was detected between the three diseased groups. 198.50 ± 38.50 = 0.000 = 0.001 = 0.005 * Values are significant when P value <0.05 o P 1 = Compared to group1 (Controls). o P 2 = Compared to group2 (IPF patients receiving steroids). o P 3 = Compared to group3 (IPF patients not-receiving steroids). Table ( 3) showed a significant increase in SP-D in the three diseased groups compared to control. There is significant increase in SP-D in non-steroidal (group 3) and patients with chronic chest diseases without IPF (group 4) compared to steroid receiving patients (group 2); also there is a significant increase in non-steroidal group compared to chronic group. 
From table (4):
A negative correlation was found between SP-D serum level and FEV1 (L) with P-value > 0.000 and r-value -0.541. In addition, a negative correlation was found between SP-D serum level and FVC (L) with P-value > 0.000 and r-value = -0.530 Also, a negative correlation was found between SP-D serum level and FEV1/FVC with P-value > 0.000 and r-value = -0.546. 
DISCUSSION
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening, interstitial lung disease of unknown etiology. For optimal therapeutic management of IPF an accurate tool is required for discrimination between reversible and irreversible types of the disease. However, such noninvasive tools are few, and even with highresolution computed tomography (HRCT), which is the most trusted method for doing so; the nature of the disease activity in IPF cannot always be accurately predicted.
Surfactant proteins (SP-A) and (SP-D) belong to the collectin subgroup of the C-type lectin superfamily, along with mannosebinding glycoproteins and collectin CL43 (2) . The aims of the present study were to assess the value of surfactant protein SP-D in determining the pathogenesis of IPF disease and if it plays a role in predicting deterioration in restrictive pulmonary function.
Also, its role in determining the therapeutic response of the patients is another aim of the present study.
The
The diagnosis of IPF was based on the accepted criteria of Carrington, et al.;
(9) which included either evidence of varying degrees of interstitial fibrosis and alveolitis, or evidence of diffuse parenchymal infiltrates on chest radiography.
SP-D in sera was measured by enzyme-linked immunosorbent assays as previously described.
The results of the study showed that pulmonary function tests represented by forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) (FEV1/FVC%) were significantly decreased in the three diseased groups compared to control.
All the patients included in the present study gave a positive history of smoking, this finding coincide with the study of Collard et al., (13) who demonstrated a strong association between cigarette smoking and pulmonary fibrosis. In the present study no significant difference was detected between the three diseased groups regarding the duration of smoking and the number of smoked cigarette/day.
The results of SP-D in the present study showed significant increase in the three diseased groups compared to control. Moreover, the mean value was significantly higher in non steroid and chronic groups compared to the steroid receiving group. Also, non steroid group was significantly higher than chronic group.
By measuring the concentrations of SP-D in sera from patients with IPF, interestingly, we found that the levels of SP-D at the initial time of study were higher in all diseased groups. Most subjects studied, even many who showed high levels of SP-D, did not have dyspnea at the initial time of study, indicating the insidious onset of the disease. Nevertheless, our results clearly indicate that high levels of SP-D are involved in the nonsteroidal group. Thus, patients exhibiting higher serum levels of SP-D may have a greater chance of falling into restrictive pulmonary dysfunction, and more rapidly, than patients with low serum levels of SP-D. Schwartz, et al., (14) suggest that it may be more effective to start treatment for IPF before the manifestations of severe pulmonary fibrosis occur. Our results raise the possibility that the assay of SP-D can help to guide therapy with corticosteroids agents.
A difference between levels of SP-D was also observed in the four studied groups. The concentration of serum SP-D probably vary with disease severity and lung inflammation (11,15,16) . The difference in the response to corticosteroid products could also affect concentrations of SP-D in serum.
Our results showed that SP-D concentration was significantly correlated with the extent of alveolitis (a reversible change), whereas they did not correlate with the progression of fibrosis (an irreversible change). The SP-D concentration was also related to the extent of parenchymal collapse and the rate of deterioration per year in pulmonary function, as proved in our study by the presence of significant negative correlation between SP-D and pulmonary function tests.
Although the exact mechanism for the increase in SP-D in the circulation is not known, it is probably a combination of a loss of epithelial integrity due to injury and an increased mass of type II cells due to hyperplasia.
Because the concentrations of serum SP-D probably vary with disease and lung inflammation, measurement of this protein might prove to be useful markers for the pathogenesis and detection of IPF (6,7,8,) . Takahashi (17) found that the concentrations of SP-A and SP-D in patients who died within 3 yr were significantly higher than in patients who were still alive after 3 yr. It has been proposed that SP-D may be a good predictive indicator of the rate of decline in pulmonary function, and that a combination of the assays for SP-A and SP-D may be helpful in predicting the outcome of patients with IPF.
Part of our results is in agreement with data from Takahashi et al. (17) and Barlo et al.
(18) who demonstrated that SP-D in serum can predict worsening in IPF patients, and that the value of SP-D remains stable after adjustment for known predictors of worsening. Takahashi et al.
(19) The author mentioned that serum SP-D level higher than 460ng/ml. indicates a significantly worse prognosis compared to levels lower than 460ng/ml. This value can be useful in clinical practice. It might help in estimating survival time, which is important for optimal timing of referral for lung transplantation.
On the basis of these findings we evaluated the utility of assays of serum SP-D in establishing the prognosis of patients with IPF. None of the patients showing SP-D levels below the respective levels died throughout the period of the study (2years). Although the number of patients in our study was small, these findings suggest that a SP-D assay is useful to identify patients with the best prognosis in IPF.
According to Kinder, et al. (20) , increased serum SP-D level is a strong and independent predictor of early mortality among patients with IPF. A prediction model containing SP-A and SP-D was substantially superior to a model with clinical predictors alone.
In conclusion, SP-D is a non-invasive marker that can be easily determined in serum and has been proved to be a diagnostic marker in IPF patients. This study adds clinically useful levels that could identify patients with a significantly worse prognosis by using SP-D for follow up of the patients. This prognostic value of SP-D persists after adjustment for known predictors of mortality. Taken all previously published studies into account, we encourage the implication of routine measurement of SP-D at the time of diagnosis in IPF patients and using it as a marker for follow up of the patient to determine the degree of worsening or improvement of the case. SP-D serum levels may assist in making clinical choices for therapeutic management of patients with IPF. 
